---
title: "Morning Trend | HAIXI PHARMA fluctuates at a high level, is the pharmaceutical leading sector under pressure?"
description: "HAIXI PHARMA (2637.HK) has recently been fluctuating at a high stage, with funds attempting to push up but lacking strength, indicating a divergence in the willingness of main funds. The pharmaceutica"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/271759883.md"
published_at: "2026-01-08T01:00:00.000Z"
---

# Morning Trend | HAIXI PHARMA fluctuates at a high level, is the pharmaceutical leading sector under pressure?

> HAIXI PHARMA (2637.HK) has recently been fluctuating at a high stage, with funds attempting to push up but lacking strength, indicating a divergence in the willingness of main funds. The pharmaceutical sector has been continuously undergoing valuation repair this year, with leading companies in the sector attracting institutions to increase their allocations due to their defensive attributes. Recently, mainstream companies have intensively released quarterly performance pre-increase announcements, triggering a simultaneous strengthening of second-tier varieties in the pharmaceutical branch concept. However, leading stocks like HAIXI PHARMA are not cooperating with increased volume at high price ranges, and the divergence between volume and price is becoming more pronounced

HAIXI PHARMA (2637.HK) has recently been fluctuating at a high level, with funds attempting to push up but lacking strength, indicating a divergence in the willingness of main funds. The pharmaceutical sector has been continuously undergoing valuation repair this year, with leading companies in the sector attracting institutions to increase their allocations due to their defensive attributes. Recently, mainstream companies have intensively released quarterly performance pre-increase announcements, triggering a synchronous strengthening of second-tier varieties in the pharmaceutical branch concept. However, leading stocks like HAIXI PHARMA have not cooperated with increased volume at high levels, and the divergence between volume and price has become more pronounced.

From a technical perspective, HAIXI PHARMA's K-line is in a bullish trend, but it has failed to effectively break through the repeated high-level area. Although the MACD remains bullish, momentum has clearly slowed down. Short-term fund interest is limited, mainly adopting a wait-and-see approach, with intraday rebounds mostly being weak upward movements, and the trading volume not expanding in sync, limiting the potential for subsequent breakthroughs. Currently, the market lacks substantial catalytic news, and the industry is still digesting the impacts of previous policies and profit announcements. If fund diversion occurs in the sector subsequently, the risk of a pullback for HAIXI PHARMA will increase. Investors need to pay attention to the changes in intraday volume and price to identify the intentions of main funds, while also tracking the marginal fluctuations in the overall healthcare sector sentiment. A prudent strategy focuses on avoiding chasing high prices and reducing risk exposure, controlling positions while considering the potential impact of cyclical adjustments

### Related Stocks

- [02637.HK - HAIXI PHARMA](https://longbridge.com/en/quote/02637.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Guotai Haitong Remains a Buy on Zai Lab Ltd (1ZLB) | Guotai Haitong analyst maintained a Buy rating on Zai Lab Ltd yesterday and set a price target of HK$27.94.Claim 50% Off | [Link](https://longbridge.com/en/news/277338249.md) |
| Shanghai XNG Terminates HK$12 Million Share Placement | Shanghai XNG Terminates HK$12 Million Share Placement | [Link](https://longbridge.com/en/news/277392488.md) |
| Suzhou Ribo Life Science's Cholesterol Medicine to Begin Phase 3 Trial | Suzhou Ribo Life Science's Cholesterol Medicine to Begin Phase 3 Trial | [Link](https://longbridge.com/en/news/277401406.md) |
| Nine Dragons Paper Holdings (NDGPF) Receives a Buy from GF Securities | GF Securities analyst maintained a Buy rating on Nine Dragons Paper Holdings yesterday and set a price target of HK$9.87 | [Link](https://longbridge.com/en/news/277339226.md) |
| Yeebo trims Nantong Jianghai stake to fund core display and AI growth | Yeebo (International Holdings) Limited has sold 9,902,000 shares in Nantong Jianghai, reducing its stake to 12.64%. The  | [Link](https://longbridge.com/en/news/276909323.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.